Clinical Trial: Evaluation of the efficacy and safety of omalizumab in the treatment of pregnant patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study (China)

Posted On: 2026-09-29

China, Sept. 29 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Evaluation of the efficacy and safety of omalizumab in the treatment of pregnant patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133492

Registration Time: 2026/09/28

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Chongqing Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=344585

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Evaluation of the efficacy and safety of omalizumab in the treatment of pregnant patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study (China)